A Double-Blind Efficacy and Safety Study of Duloxetine Fixed Doses in Children and Adolescents with Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of duloxetine fixed dose in the treatment of children (7-11 years) and adolescents (12-17 years) with major depressive disorder (MDD). METHODS: Patients (n=463) in this 36 week study (10 week acute and 26 week extension treatment) received duloxetine 60 mg QD (n=108), duloxetine 30 mg QD (n=116), fluoxetine 20 mg QD (n=117, active control), or placebo (n=122). Measures included: Children's Depression Rating Scale-Revised (CDRS-R), treatment-emergent adverse events (TEAEs), and Columbia-Suicide Severity Rating Scale (C-SSRS). RESULTS: Neither active drug (duloxetine or fluoxetine) separated significantly (p<0.05) from placebo on mean change from baseline to end-point (10 weeks) on the CDRS-R total score. Total TEAEs and discontinuation for AEs were significantly (p<0.05) higher only for the duloxetine 60 mg group versus the placebo group during acute treatment. No clinically significant electrocardiogram (ECG) or laboratory abnormalities were observed, and no completed suicides or deaths occurred during the study. A total of 7 (6.7%) duloxetine 60 mg, 6 (5.2%) duloxetine 30 mg, 9 (8.0%) fluoxetine, and 11 (9.4%) placebo patients had worsening of suicidal ideation from baseline during acute treatment. Of the patients with suicidal ideation at baseline, 13/16 (81%) duloxetine 60 mg, 16/17 (94%) duloxetine 30 mg, 11/16 (69%) fluoxetine, and 13/15 (87%) placebo had improvement in suicidal ideation at end-point during acute treatment. One fluoxetine, one placebo, and six duloxetine patients had treatment-emergent suicidal behavior during the 36 week study. CONCLUSIONS: Trial results were inconclusive, as neither the investigational drug (duloxetine) nor the active control (fluoxetine) separated from placebo on the CDRS-R at 10 weeks. No new duloxetine safety signals were identified relative to those seen in adults. Clinical Trial Registry Number ( www.ClinicalTrials.gov ): NCT00849693.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 15×
“Also during the acute treatment period, two patients reported suicidal behavior (nonfatal suicide attempt) on the C-SSRS.”
MethodInfluentialSmall sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552 · cited 1×
“A Kenward–Roger correction (Kenward and Roger 1997) was used to estimate denominator degrees of freedom.”
MethodECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Sheehan, D. V., Sheehan, K. H., Shytle, R. D., Janavs, J., Bannon, Y., Rogers, J. E., Milo, K. M., Stock, S. L., & Wilkinson, B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05305whi · Cited by 1,730
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256 · cited 2×
“Such factors related to study size have been proposed as the better predictors of placebo response in studies of pediatric MDD patients (Bridge et al. 2009).”
BackgroundEmslie, G. J., Ventura, D., Korotzer, A., & Tourkodimitris, S. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181a2b304 · Cited by 210 · cited 1×
“Fluoxetine has shown replicate efficacy in the treatment of children and adolescents with MDD (Emslie et al. 1997, 2002) and escitalopram has shown replicate efficacy in adolescents (Wagner et al. 2006; Emslie et al. 2009).”
BackgroundSelf-citationHeiligenstein, J. H., Hoog, S. L., Wagner, K. D., Findling, R. L., Galil, N., Kaplan, S., Busner, J., Nilsson, M. E., Brown, E. B., & Jacobson, J. G. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.207 · Cited by 39
Cited by
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Walkup, J. T. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091059 · Cited by 112
Strawn, J. R., Mills, J. A., Sauley, B. A., & Welge, J. A. (2018) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2018.01.015 · Cited by 98
Courtney, D. B., Watson, P., Krause, K. R., Chan, B. W. C., Bennett, K., Gunlicks-Stoessel, M., Rodak, T., Neprily, K., Zentner, T., & Szatmari, P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.46331 · Cited by 63
Zhong, Z., Wang, L., Wen, X., Liu, Y., Fan, Y., & Liu, Z. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s141832 · Cited by 46
“26 Emslie et al 2014 29,a Emslie et al 2014 29 , b Emslie et al 2015 30 Atkinson et al 2014 40 Oslin et al 2003 24”
Ignaszewski, M. J., & Waslick, B. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0174 · Cited by 37
“For patients initially randomized to duloxetine 60 mg, there was no statistically significant probability of remission at 36 weeks (81%) compared with those randomized initially to fluoxetine 20 mg (74%) (Emslie et al. 2014).”
InfluentialRohden, A. I., Benchaya, M. C., Camargo, R. S., Moreira, T. D. C., Barros, H. M. T., & Ferigolo, M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.017 · Cited by 35
Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder
Blanco, C., Hoertel, N., Franco, S., Olfson, M., He, J.-P., López, S., González-Pinto, A., Limosin, F., & Merikangas, K. R. (2017) · Pediatrics · doi:10.1542/peds.2016-1701 · Cited by 29
Xu, Y., Bai, S. J., Lan, X. H., Qin, B., Huang, T., & Xie, P. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20164806 · Cited by 24
Twenty years of progress in paediatric psychopharmacology: accomplishments and unmet needs
Vitiello, B., & Davico, C. (2018) · Evidence Based Mental Health · doi:10.1136/ebmental-2018-300040 · Cited by 21
Metadata
- Authors
- Emslie, G. J., Prakash, A., Zhang, Q., Pangallo, B. A., Bangs, M. E., & March, J. S.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2014-05
- Volume
- 24
- Issue
- 4
- Pages
- 170-179
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2320774618
- Cited by
- 106
- References
- 9
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.